ARMP News - Candlesense

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(ARMP) LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development o...

Corporate

4 days ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES, Aug. 12, 2025 /PRN...

What is the broader market sentiment toward mid‑stage biotech companies with similar cash‑flow profiles, and how might this news shift investor positioning in ARMP? Are there any contingent milestones or covenants tied to the credit agreement that could affect future financing flexibility? How might the Phase 1b/2a results impact the timeline for regulatory submissions and eventual market launch of AP‑SA02?

Earnings

26 days ago